TerminatedNCT00946985

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Medication studyAges 18–35Multiple countries

The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 35 years.

Listed locations: Little Rock and 71 more locationsSee all locations and recruitment
Study phase: Phase 4

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJune 2009

Recruitment status: Terminated
Enrollment listed in the registry: 163
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: United States, Canada, Brazil, ...
Age range: From 18 Years to 35 Years
Official registry ID: NCT00946985
Official title: Show the full official title
A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate With Oral Risperidone in Adults With Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse

Questions about this study?

The HopeStage team will email you.

Recruitment & locations

Terminated

Little Rock, United States · Garden Grove, United States · San Diego, United States

71 more locations

Washington D.C., United States
Kissimmee, United States
Tampa, United States
Chicago, United States
Hoffman Estates, United States
Kingsport, United States
Lake Charles, United States
Shreveport, United States
Pittsfield, United States
Minneapolis, United States
Flowood, United States
Creve Coeur, United States
St Louis, United States
Omaha, United States
Brooklyn, United States
Middleburg Heights, United States
Arlington, United States
Austin, United States
Irving, United States
Portsmount, United States
Curitiba, Brazil
Salvador, Brazil
São Paulo, Brazil
Kazanlak, Bulgaria
Pleven, Bulgaria
Radnevo, Bulgaria
Calgary, Canada
Halifax, Canada
Greater Sudbury, Canada
Montreal, Canada
Québec, Canada
Baoding, China
Beijing, China
Changsha, China
Guangzhou, China
Kunming, China
Shanghai, China
Wuhan, China
Xi'an, China
Bogotá, Colombia
Kutná Hora, Czechia
Olomouc, Czechia
Prague, Czechia
Strakonice, Czechia
Ahmedabad, India
Aurangabad, India
Calicut, India
Hyderabad, India
Jaipur, India
Lucknow Gpo, India
Mangalore, India
Pune, India
Varanasi, India
Johor Bahru, Malaysia
Kuala Lumpur, Malaysia
Moscow, Russia
Nizny Novgorod, Russia
Saint Petersburg, Russia
Samara, Russia
Yaroslavl, Russia
Gwangju, South Korea
Gyeonggi-do, South Korea
Jeonju, South Korea
Seoul, South Korea
Kharkiv, Ukraine
Kherson, Ukraine
Kiev, Ukraine
Odesa, Ukraine
Simferopol, Ukraine
Czechia
Russia

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Ortho-McNeil Janssen Scientific Affairs, LLC.

Does this study involve medication?

Yes. The study involves medication, including paliperidone palmitate and oral risperidone.

Who can participate?

Listed age limits: 18 years to 35 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me